ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDKN2A (Cyclin-dependent kinase inhibitor 2A), EGFR (Epidermal growth factor receptor)
See More ...
ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDKN2A (Cyclin-dependent kinase inhibitor 2A), EGFR (Epidermal growth factor receptor), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), HER-2 (Human epidermal growth factor receptor 2), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KIT (KIT proto-oncogene, receptor tyrosine kinase), MET (MET proto-oncogene, receptor tyrosine kinase), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), NTRK (Neurotrophic receptor tyrosine kinase), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PTEN (Phosphatase and tensin homolog), RB1 (RB Transcriptional Corepressor 1), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TERT (Telomerase Reverse Transcriptase), TP53 (Tumor protein P53)